Main weaknesses include lack of tumor genomic characterization (beyond the absence of activating EGFR and ALK alterations), inclusion of only cytotoxic and antiangiogenic therapies, lack of information on postprogression therapy, and exclusion of squamous tumors. This evidence concerns the gene ALK and neoplasm.